Safety Study of HSK31858 for Bronchiectasis
Treatments studied
Part of Lungs & breathing clinical trials.
This study tests how safe an experimental inhaled medicine (HSK31858) is for people with non-cystic fibrosis bronchiectasis, a lung condition where airways are damaged and collect mucus. You can only join if you already completed a previous HSK31858 study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already participated in the HSK31858-301 study and taken at least one dose of the medicine
- If you use long-acting bronchodilators (breathing medicines), you must keep taking them at the same dose throughout this study
- Women must be past menopause, unable to have children, or use reliable birth control for 30 days after the last dose
- Men with partners who can get pregnant must use effective birth control for 90 days after the last dose
- You cannot have had a serious allergic or bad reaction to HSK31858 in the previous study
- You must not have any unstable heart, stomach, liver, kidney, nerve, or blood conditions that could affect your safety
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, HSK31858, for people with non-cystic fibrosis bronchiectasis (a lung condition causing chronic cough and infections). It aims to see if the drug reduces lung flare-ups and improves symptoms.
This trial tests an inhaled medication called CSL787 to see if it can help people with non-cystic fibrosis bronchiectasis (a lung condition that causes frequent infections and breathing problems). The study looks at different doses and checks how well the drug works and if it is safe.
This trial tests an inhaled drug called ensifentrine in people with bronchiectasis (damaged, widened airways in the lungs). The goal is to see if it can reduce flare-ups and improve symptoms.
This study tests an inhaled medicine (GDC-6988) to see if it is safe and helps clear mucus from the lungs in people with mucus-related lung diseases like chronic bronchitis, COPD, or bronchiectasis. You may qualify if your lung function is fairly stable and you produce daily mucus.
This trial tests whether inhaling a saltwater solution (hypertonic saline) twice a day for 12 weeks can help people with bronchiectasis who have a chronic cough and have had flare-ups in the past. It aims to see if this treatment reduces mucus and improves quality of life.
This study tests a new inhaled medication called HSK39004 for people with COPD. The goal is to see if it is safe and effective over the long term, and to compare it with a placebo to find out how well it helps with breathing.
Hear when a new Non-cystic Fibrosis Bronchiectasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.